Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
Background: The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast can
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 28, Heft: 4, Pages: 754-760 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw665 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw665 Verlag, Volltext: https://academic.oup.com/annonc/article/28/4/754/2716543 
|
| Verfasserangaben: | R. Bell, J. Brown, M. Parmar, M. Toi, T. Suter, G. G. Steger, X. Pivot, J. Mackey, C. Jackisch, R. Dent, P. Hall, N. Xu, L. Morales, L. Provencher, R. Hegg, L. Vanlemmens, A. Kirsch, A. Schneeweiss, N. Masuda, F. Overkamp, D. Cameron |
| Zusammenfassung: | Background: The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast can |
|---|---|
| Beschreibung: | Gesehen am 13.07.2018 Published online 19 December 2016 |
| Beschreibung: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw665 |